Quick answers
- What is Auryxia?
- Auryxia is a brand name of Ferric citrate (tetraferric tricitrate decahydrate), a prescription medicine. The FDA NDC Directory lists 1 Auryxia product in 1 strength and form.
- Who makes Auryxia?
- Keryx Biopharms holds the FDA application for Auryxia (NDA205874, approved September 5, 2014).
- Is there a generic or store brand of Auryxia?
- Yes. The FDA NDC Directory lists 1 other product with the same active ingredients, strength and form as a Auryxia product, 1 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Auryxia?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Auryxia strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Auryxia been recalled?
- FDA enforcement reports list 4 recalls of Auryxia products; the newest started March 15, 2021. A recall usually concerns specific lots, not every product.
What Auryxia is
Each Auryxia product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Ferric citrate (tetraferric tricitrate decahydrate) · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| tetraferric tricitrate decahydrate 210 mg tablet, film coated (oral) | Auryxia | 1 product, 1 company | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ferric citrate (tetraferric tricitrate decahydrate) →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA205874 | Keryx Biopharms | September 5, 2014 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| tetraferric tricitrate decahydrate 210 mg tablet, film coated | Brand: Auryxia | $7.48 per tablet Generic of the same strength and form: $6.37 per tablet |
NADAC list of November 4, 2026; these prices took effect on February 18, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Auryxia
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Auryxia products.
- Akebia Therapeutics, Inc.1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0499-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Auryxia (ferric citrate) tablets 210 mg* 200 Tablets Rx Only NDC 59922-631-01 Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc. 750 Lexington Avenue, 20th Floor New York, NY 10022 USA — Cardinal Health Inc.
-
December 9, 2020 · Class II · Terminated · D-0170-2021
CGMP Deviations
Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA 02210, NDC 59922-631-01 — Akebia Therapeutics dba Keryx Biopharmaceutials, Inc
-
July 10, 2020 · Class II · Terminated · D-1389-2020
cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.
Auryxia (ferric citrate) tablets 210 mg, Rx Only, 200 tablets per bottle, Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc., 245 First Street Suite 1400, Cambridge, MA 02142, NDC: 59922-631-01. — Keryx Biopharmaceuticals, Inc.
-
December 12, 2017 · Class III · Terminated · D-0133-2018
Presence of Foreign Substance: Reports have been received of damaged StripPax packets containing silica gel desiccant potentially allowing the silica gel granules to make contact with Auryxia tablets in the bottle.
Auryxia (ferric citrate) tablets, 210 mg , 200-count bottles, RX ONLY, Manufactured for and distributed by: Keryx Biopharmaceticals, Inc. One Marina Park Drive, 12th Floor, Boston, MA 02210 USA. NDC 59922-631-01 — Keryx Biopharmaceuticals, Inc.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.